• 1
    Wang MC,Valenzuela LA,Murphy GP,Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979; 17: 159163.
  • 2
    Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985; 76: 18991903.
  • 3
    Stamey TA,Yang N,Hay AR,McNeal JE,Freiha FS,Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909916.
  • 4
    Cooner WH,Mosley BR,Rutherford CLJr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990; 143: 11461152; discussion 1152–1144.
  • 5
    Catalona WJ,Smith DS,Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324: 11561161.
  • 6
    Brawer MK,Chetner MP,Beatie J,Buchner DM,Vessella RL,Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992; 147(3 pt 2): 841845.
  • 7
    Terris MK,Stamey TA. Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values. Br J Urol. 1994; 73: 6164.
  • 8
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 4366.
  • 9
    D'Amico AV,Whittington R,Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969974.
  • 10
    Chodak GW,Keller P,Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol. 1989; 141: 11361138.
  • 11
    Catalona WJ,Smith DS,Ratliff TL,Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993; 270: 948954.
  • 12
    Smith DS,Catalona WJ,Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996; 276: 13091315.
  • 13
    Amling CL,Blute ML,Lerner SE,Bergstralh EJ,Bostwick DG,Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 1998; 73: 401406.
  • 14
    Farkas A,Schneider D,Perrotti M,Cummings KB,Ward WS. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology. 1998; 52: 444448; discussion 448–449.
  • 15
    Jhaveri FM,Klein EA,Kupelian PA,Zippe C,Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999; 17: 31673172.
  • 16
    Han M,Partin AW,Piantadosi S,Epstein JI,Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001; 166: 416419.
  • 17
    Pickles T,Coldman A,Phillips N. The changing face of prostate cancer in British Columbia 1988-2000. Can J Urol. 2002; 9: 15511557.
  • 18
    Paquette EL,Sun L,Paquette LR,Connelly R,McLeod DG,Moul JW. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology. 2002; 60: 756759.
  • 19
    Ung JO,Richie JP,Chen MH,Renshaw AA,D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology. 2002; 60: 458463.
  • 20
    Cooperberg MR,Lubeck DP,Mehta SS,Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003; 170(6 pt 2): S21S25; discussion S26–S27.
  • 21
    Zebic N,Roggenbuck U,Mandt D,Kropfl D. Migrations in clinical and pathological stage of prostatic carcinoma in patients undergoing radical prostatectomy in the period between 1993 and 2003. Coll Antropol. 2005; 29: 593598.
  • 22
    Galper SL,Chen MH,Catalona WJ,Roehl KA,Richie JP,D'Amico AV. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol. 2006; 175(3 pt 1): 907912.
  • 23
    Ryan CJ,Elkin EP,Small EJ,Duchane J,Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol. 2006; 24: 396402.
  • 24
    D'Amico AV,Chen MH,Roehl KA,Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004; 351: 125135.
  • 25
    D'Amico AV,Renshaw AA,Sussman B,Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005; 294: 440447.
  • 26
    Patel DA,Presti JCJr,McNeal JE,Gill H,Brooks JD,King CR. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 2005; 23: 61576162.
  • 27
    GreeneFL,PageDL,FlemingID, et al, eds. AJCC Cancer Staging Manual,6th ed. New York, NY: Springer-Verlag; 2002.
  • 28
    Andriole GL,Reding D,Hayes RB,Prorok PC,Gohagan JK. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: status and promise. Urol Oncol. 2004; 22: 358361.
  • 29
    de Koning HJ,Auvinen A,Berenguer Sanchez A, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer trial. Int J Cancer. 2002; 97: 237244.